Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177347 | 0.86 | DRD2 (0.50) | RAB9ADRD2DRD3DRD4DRD1 | |
| SCHEMBL5187761 | 0.84 | DRD2 (0.51) | HPGDGAADRD2DRD3DRD4 | |
| SCHEMBL5900971 | 0.84 | DDR1 (0.55) | HPGDGAARAB9ADRD2DRD3 | |
| SCHEMBL5178413 | 0.84 | DRD2 (0.54) | HPGDDRD2DRD3DRD4DRD1 | |
| SCHEMBL5177140 | 0.83 | MEN1 (0.51) | HPGDDRD2DRD3DRD4TMEM97 | |
| SCHEMBL5900654 | 0.82 | HPGD (0.58) | HPGDGAAMMP13RAB9ADRD2 | |
| SCHEMBL5177817 | 0.81 | SMPD1 (0.53) | HPGDRAB9ADRD2DRD3LMNA | |
| SCHEMBL5186845 | 0.78 | EPHX2 (0.53) | DRD2DRD3DRD4EPHX2 | |
| SCHEMBL5176636 | 0.78 | DRD2 (0.44) | DRD2DRD3DRD4EPHX2 | |
| SCHEMBL5187787 | 0.77 | DRD2 (0.42) | DRD2DRD3DRD4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791810-A1 | 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIA INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006027135-A1 | 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIIA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | F7, HABP2, F12 | HPGD 1587/4885GAA 890/4885MMP13 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.